Category Archives: Gastrointestinal

1. ESMOupdate 2012, Gastrointestinal Cancers

Dr. med. Sabina Schacher und Dr. med. Daniel Helbling besprechen die wichtigsten, klinisch relevanten Studien im Bereich Gastrointestinal Cancers, die am diesjährigen ESMO (European Society for Medical Onocology) Meeting in Wien präsentiert wurden.

Diskutierte Studien:
LBA18: Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC): Overall survival update; E. van Cutsem et al

LBA17: A randomized phase III study evaluating the continuation of bevacizumab (BV) beyond progression in metastatic colorectal cancer (mCRC) patients (pts) who received BV as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord; G. Masi et al

4. ASCOupdate 2011, Gastrointestinale Tumore

Diskussionsleiter Dr. D. Helbling, OnkoZentrum Zürich, bespricht folgende Studien:

Abstract 3520: An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM)

Abstract LBA1: Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: Final results of a randomized trial (SSGXVIII/AIO)

Abstract LBA4002: Adjuvant capecitabine and oxaliplatin for gastric cancer: Results of the phase III CLASSIC trial

Abstract 4000: Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)

Abstract 4004: A multicenter, randomized phase III trial comparing second-line chemotherapy (SLC) plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC)

Abstract 3511: Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab